A bill introduced today in the Vermont Senate would extend and expand the state’s Psychedelic Therapy Advisory Working Group, which has been studying the potential therapeutic benefits of psychedelics for mental health treatment.
Vermont State Capitol Building.
Senate Bill 106, sponsored by Senators Gulick, Vyhovsky, and White, all Democrat, has been referred to the Senate Committee on Health and Welfare for further consideration.
If passed, the bill would continue the group’s work reviewing research on psychedelics, including their potential role in treating conditions such as depression and anxiety, particularly in patients with serious illnesses or nearing the end of life.
The measure would also add new members to the group, including an expert in psychedelic treatment affiliated with a Vermont hospital that provides ketamine therapy, a mental health professional with specialized training in psychedelic medicine, an attorney with healthcare experience, and a public representative.
The working group would also be tasked with monitoring psychedelic programs in other states and considering how Vermont could implement harm reduction training and public education on substances such as psilocybin.
The bill directs the group to submit a report with recommendations to the legislature by November 15, 2025. If enacted, the working group would continue operating until January 1, 2026.
